GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics ...

Ocular Therapeutixtm Appoints David W. Robinson As Global Chief Commercial Officer. Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat ...

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

RAPT Therapeutics stock surged over 63% after GSK agreed to buy the company for $58 per share in a $2.2 billion deal.

GSK has agreed to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel ...

RAPT Therapeutics shares surged after GSK agreed to acquire the biotech for $2.2 billion, adding a promising food allergy ...

US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults ...

South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...

The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.